High incidence of tacrolimus-associated posttransplantation diabetes in the Korean renal allopraft recipients according to American Diabetes Association criteria

Diabetes Care

Volumn 26, Issue 4, 2003, Pages 1123-1128

  Cho, Young Min ^a   Park, Kyong Soo ^a   Jung, Hye Seung ^a   Jeon, Hyun Jung ^a   Ahn, Curie ^a   Ha, Jongwon ^a   Kim, Sang Joon ^a   Rhee, Byoung Doo ^b   Kim, Seong Yeon ^a   Lee, Hong Kyu ^a  

^a Seoul National University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; INSULIN; TACROLIMUS;

ADULT; AGE; AGING; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIET RESTRICTION; DOSE RESPONSE; FEMALE; FOLLOW UP; GRAFT REJECTION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INSULIN RELEASE; INSULIN RESISTANCE; KIDNEY ALLOGRAFT; KIDNEY TRANSPLANTATION; MALE; ORAL GLUCOSE TOLERANCE TEST; RECIPIENT; RISK FACTOR;

ADULT; C-PEPTIDE; CHOLESTEROL; DIABETES MELLITUS; FEMALE; FOLLOW-UP STUDIES; GLUCOSE TOLERANCE TEST; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; INSULIN; KIDNEY TRANSPLANTATION; MALE; POSTOPERATIVE COMPLICATIONS; SOCIETIES, MEDICAL; TACROLIMUS; TIME FACTORS; TRIGLYCERIDES; UNITED STATES;

EID: 0042167544     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.26.4.1123     Document Type: Article

References (39)

1. Shapiro R, Jordan M, Scantlebury V, Fung J, Jensen C, Tzakis A, McCauley J, Carroll P, Ricordi C, Demetris AJ, Mitchell S, Jain A, Iwaki Y, Kobayashi M, Reyes J, Todo S, Hakala TR, Simmons RL, Starzl TE: FK 506 in clinical kidney transplantation. Transplant Proc 23:3065-3067, 1991
2. Japanese FK506 study group: Japanese study of FK 506 on kidney transplantation: results of late phase II study. Transplant Proc 25:649-654, 1993
3. Schleibner S, Krauss M, Wagner K, Erhard J, Christiaans M, van Hooff J, Buist L, Mayer D: FK 506 versus cyclosporin in the prevention of renal allograft rejection: European pilot study: six-week results. Transpl Int 8:86-90, 1995
4. Pirsch JD, Miller J, Deierhoi MH, Vincenti F, Filo RS: A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation: FK506 Kidney Transplant Study Group. Transplantation 63:977-983, 1997
5. Montori VM, Basu A, Erwin PJ, Velosa JA, Gabriel SE, Kudva YC: Posttransplantation diabetes: a systematic review of the literature. Diabetes Care 25:583-592, 2002
6. van Hooff JP, Christiaans MH: Use of tacrolimus in renal transplantation. Transplant Proc 31:3298-3299, 1999
7. Knoll GA, Bell RC: Tacrolimus versus cyclosporin for immunosuppression in renal transplantation: meta-analysis of randomised trials. BMJ 318:1104-1107, 1999
8. Scantlebury V, Shapiro R, Fung J, Tzakis A, McCauley J, Jordan M, Jensen C, Hakala T, Simmons R, Starzl TE: New onset of diabetes in FK 506 vs cyclosporine-treated kidney transplant recipients. Transplant Proc 23:3169-3170, 1991
9. Furth S, Neu A, Colombani P, Plotnick L, Turner ME, Fivush B: Diabetes as a complication of tacrolimus (FK506) in pediatric renal transplant patients. Pediatr Nephrol 10:64-66, 1996
10. Tanabe K, Koga S, Takahashi K, Sonda K, Tokumoto T, Babazono T, Yagisawa T, Toma H, Kawai T, Fuchinoue S, Teraoka S, Ota K: Diabetes mellitus after renal transplantation under FK 506 (tacrolimus) as primary immunosuppression. Transplant Proc 28:1304-1305, 1996
11. Khoury N, Kriaa F, Hiesse C, Von Ey F, Durbach A, Ammor M, Hafi A, Djeffal R, Boubenider S, Droupy S, Hammoudi Y, Eschwege P, Benoit G, Charpentier B: Posttransplant diabetes mellitus in kidney transplant recipients under tacrolimus immunosuppression. Transplant Proc 32: 2763-2764, 2000
12. Panz VR, Bonegio R, Raal FJ, Maher H, Hsu HC, Joffe BI: Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation. Transplantation 73:587-590, 2002
13. Tamura K, Fujimura T, Tsutsumi T, Nakamura K, Ogawa T, Atumaru C, Hirano Y, Ohara K, Ohtsuka K, Shimomura K, Kobayashi M: Transcriptional inhibition of insulin by FK506 and possible involvement of FK506 binding protein-12 in pancreatic beta-cell. Transplantation 59: 1606-1613, 1995
14. Redmon JB, Olson LK, Armstrong MB, Greene MJ, Robertson RP: Effects of tacrolimus (FK506) on human insulin gene expression, insulin mRNA levels, and insulin secretion in HIT-T15 cells. J Clin Invest 98:2786-2793, 1996
15. Morrisett JD, Abdet-Fattah G, Hoogeveen R, Mitchell E, Ballantyne CM, Pownall HJ, Opekun AR, Jaffe JS, Oppermann S, Kahan BD: Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients. J Lipid Res 43:1170-1180, 2002
16. Hirano Y, Fujihira S, Ohara K, Katsuki S, Noguchi H: Morphological and functional changes of islets of Langerhans in FK506-treated rats. Transplantation 53: 889-894, 1992
17. Cho YM, Park KS, Jung HS, Kim YS, Kim SY, Lee HK: A case showing complete insulin independence after severe diabetic ketoacidosis associated with tacrolimus treatment (Letter). Diabetes Care 25:1664, 2002
18. Miles AM, Sumrani N, Horowitz R, Homel P, Maursky V, Markell MS, Distant DA, Hong JH, Sommer BG, Friedman EA: Diabetes mellitus after renal transplantation: as deleterious as non-transplant-associated diabetes? Transplantation 65: 380-384, 1998
19. The Diabetes Control and Complication Trial Research Group: The absence of a glycemic threshold for the development of long-term complications: the perspective of the Diabetes Control and Complications Trial. Diabetes 45:1289-1298, 1996
20. UK Prospective Diabetes Study Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352:837-853, 1998
21. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-1197, 1997
22. Neylan JF: Racial differences in renal transplantation after immunosuppression with tacrolimus versus cyclosporine. Transplantation 65:515-523, 1998
23. Hricik DE, Anton HA, Knauss TC, Rodriguez V, Seaman D, Siegel C, Valente J, Schulak JA: Outcomes of African American kidney transplant recipients treated with sirolimus, tacrolimus, and corticosteroids. Transplantation 74:189-193, 2002
24. Min HK: Non-insulin-dependent diabetes mellitus (NIDDM) in Korea. Diabet Med 13:S13-15, 1996
25. Shin CS, Lee HK, Koh C-S, Kim YI, Shin YS, Yoo KY, Paik HY, Park YS, Yang BG: Risk factors for the development of NIDDM in Yonchon County, Korea. Diabetes Care 20:1842-1846, 1997
26. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28:412-419, 1985
27. Pratley RE, Weyer C: The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 44:929-945, 2001
28. Park Y, Lee H, Koh C-S, Min H, Yoo K, Kim Y, Shin Y: Prevalence of diabetes and IGT in Yonchon County, South Korea. Diabetes Care 18:545-548, 1995
29. Nam JH, Mun JI, Kim SI, Kang SW, Choi KH, Park K, Ahn CW, Cha BS, Song YD, Lim SK, Kim KR, Lee HC, Huh KB: β-Cell dysfunction rather than insulin resistance is the main contributing factor for the development of postrenal transplantation diabetes mellitus. Transplantation 71: 1417-1423, 2001
30. Charles MA, Eschwege E, Thibult N, Claude JR, Wamet JM, Rosselin GE, Girard J, Balkau B: The role of non-esterified fatty acids in the deterioration of glucose tolerance in Caucasian subjects: results of the Paris Prospective Study. Diabetologia 40:1101-1106, 1997
31. Baid S, Tolkoff-Rubin N, Farrell ML, Delmonico F, Williams WW, Hayden D, Ko D, Cosimi AB, Pascual M: Tacrolimus-associated posttransplant diabetes mellitus in renal transplant recipients: role of hepatitis C infection. Transplant Proc 34: 1771-1773, 2002
32. Uchida K, Tominaga Y, Haba T, Katayama A, Ichimori T, Yamada K, Hibi Y, Uemura O, Morozumi K, Takagi H: Decreasing pancreatic toxicity of tacrolimus by dosage reduction. Transplant Proc 30:1276-1278, 1998
33. Weir GC, Laybutt DR, Kaneto H, Bonner-Weir S, Sharma A: β-Cell adaptation and decompensation during the progression of diabetes. Diabetes 50 (Suppl. 1): S154-S159, 2001
34. Shapiro R, Scantlebury VP, Jordan ML, Vivas C, Gritsch HA, McCauley J, Fung JJ, Hakala TR, Simmons RL, Starzl TE: Reversibility of tacrolimus-induced posttransplant diabetes: an illustrative case and review of the literature. Transplant Proc 29:2737-2738, 1997
35. van Duijnhoven EM, Christiaans MH, Boots JM, Nieman FH, Wolffenbuttel BH, van Hooff JP: Glucose metabolism in the first 3 years after renal transplantation in patients receiving tacrolimus versus cyclosporine-based immunosuppression. J Am Soc Nephrol 13:213-220, 2002
36. Shapiro AM, Lakey JR, Ryan EA, Korbutt GS, Toth E, Warnock GL, Kneteman NM, Rajotte RV: Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen. N Engl J Med 343:230-238, 2000
37. Ciancio G, Burke GW, Suzart K, Roth D, Kupin W, Rosen A, Olson L, Esquenazi V, Miller J: Daclizumab induction, tacrolimus, mycophenolate mofetil and steroids as an immunosuppression regimen for primary kidney transplant recipients. Transplantation 73:1100-1106, 2002
38. Yoshioka K, Sato T, Okada N, Ishii T, Imanishi M, Tanaka S, Kim T, Sugimoto T, Fujii S: Post-transplant diabetes with anti-glutamic acid decarboxylase antibody during tacrolimus therapy. Diabetes Res Clin Pract 42:85-89, 1998
39. Ahn KJ, Kim YS, Lee HC, Park K, Huh KB: Clinical characteristics and possible risk factors in postrenal transplant diabetes mellitus. Transplant Proc 24:1581-1582, 1992